BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: PARPi selectively kill cancer cells with homologous recombination repair deficiency (HRD), as a result, PARPi are widely employed to treated BRCA1/2-mutant ovarian, breast, pancreatic and prostate cancers.